Sanofi Ventures operates as an evergreen corporate VC with over $1.4B in assets that spans the full company lifecycle from seed to IPO, positioning itself as Sanofi's key vehicle to become an AI-powered biopharma company through investments in AI drug discovery and clinical development tools. The fund differentiates itself by offering founders both top-tier VC governance and structured access to Sanofi's internal capabilities across science, development, regulatory, and commercialization, while using equity investing as a scouting mechanism for emerging therapeutic areas where Sanofi wants to build a footprint.